Brian Lian, Viking Therapeutics CEO
June 4, 2024 10:57 AM EDT
R&D

Viking ex­pands on Phase 2b da­ta for NASH drug, tout­ing his­to­log­i­cal end­points

Max Gelman

Senior Editor

Viking Ther­a­peu­tics an­nounced Tues­day morn­ing new da­ta from a Phase 2b tri­al look­ing at its NASH drug, aim­ing to pro­vide a fuller pic­ture of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times